Remove Bioinformatics Remove Protein Remove Trials
article thumbnail

CancerVar: A New Bioinformatics Tool Developed for Clinical Interpretation of Cancer Mutations

XTalks

On Saturday, researchers at the Children’s Hospital of Philadelphia (CHOP) have announced that they developed and launched a new bioinformatics software tool called CancerVar (cancer variant interpretation). XTALKS WEBINAR: Harnessing Artificial Intelligence for Higher Quality Data in Preclinical Trials and Translational Research.

article thumbnail

Eisai-backed trial will assess Altoida’s digital test for early Alzheimer’s

pharmaphorum

A software platform developed by Altoida that uses augmented reality and artificial intelligence to diagnose neurological diseases in their earliest stages is being tested in a five-year trial involving thousands of patients.

Trials 78
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Country focus: Hungary carves out a niche in digital pharma

pharmaphorum

“For example, you can simulate what would happen if you inhibited thousands of different proteins in thousands of different cell models.”. They go into bioinformatics”. They go into bioinformatics.”. There are a lot of scientists who want to better understand biology but don’t have the money to do it in wet settings.

article thumbnail

The future of genomic medicine: can it fulfil its promises?

pharmaphorum

While there may be just under 20,000 confirmed protein coding genes, it turns out that much of the genome outside of these genes is also important in regulating how the genome is controlled. Genomics also means we will be able to stratify patients, based upon their genomic makeup, to make clinical trials much more efficient and targeted.

Genome 119
article thumbnail

Big pharma companies partner to form AI-based start-up

pharmaphorum

AION Labs’ third call for applications seeks computational biologists, bioinformatics and cheminformatics scientists, AI researchers, and antibody or protein engineers at academic and industry research labs worldwide to assemble a fully funded start-up company.

article thumbnail

Amgen To Acquire Privately Held Teneobio For $900 Million In Cash With Future Contingent Milestone Payments

The Pharma Data

Teneobio’s discovery platform, TeneoSeek, comprises genetically engineered animals (UniRat® and OmniFlic®), next-generation sequencing, bioinformatics and high-throughput vector assembly technologies. TeneoSeek rapidly identifies large numbers of unique binding molecules specific for therapeutic targets of interest.

article thumbnail

Breaking Barriers in Solid Tumor Research: Precision Medicine & Strategic Operations

Worldwide Clinical Trials

Have you optimized your trial designs to employ precision medicine approaches for your novel solid tumor intervention? Integrate Biomarkers Where Possible Biomarker integration is crucial in solid tumor clinical trials, though more research is needed before fully validated assays become the norm across solid tumor indications.

Medicine 100